Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
Anti-CD20-treated primary progressive multiple sclerosis patients have higher risk for serious infection
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.